NCT00134238

Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.

Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 755 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with mixed hyperlipidemia

Detailed description

For additional information please call: 1-800-718-1021

Conditions

• Mixed Hyperlipidemia

Interventions

Type	Name	Description
DRUG	torcetrapib/atorvastatin
DRUG	atorvastatin

Timeline

• Start date: 2003-11-01
• Primary completion: 2006-12-01
• Completion: 2006-12-01
• First posted: 2005-08-24
• Last updated: 2012-02-17

Locations

51 sites across 6 countries: United States, Canada, Czechia, Finland, France, Netherlands